Could a diabetes drug boost chemo for tough cancers?

NCT ID NCT07627191

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide injections alongside their first-line chemo. The main goal is to check for serious side effects and see if patients can complete their planned chemo without dose changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide (GLP-1 receptor agonist)
What this could lead to
If it works, this could show that adding semaglutide to standard chemotherapy is safe and tolerable, potentially improving treatment outcomes for these cancers.
What could go wrong
This is a very early, small trial (30 people) that hasn't started yet. It only tests safety and tolerability, not whether it actually helps fight cancer. Side effects from semaglutide or interactions with chemo are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Arizona Cancer Center

    Tucson, Arizona, 85724, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.